JP2014509655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509655A5 JP2014509655A5 JP2014502835A JP2014502835A JP2014509655A5 JP 2014509655 A5 JP2014509655 A5 JP 2014509655A5 JP 2014502835 A JP2014502835 A JP 2014502835A JP 2014502835 A JP2014502835 A JP 2014502835A JP 2014509655 A5 JP2014509655 A5 JP 2014509655A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- diazepam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 22
- 229960003529 diazepam Drugs 0.000 claims 20
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 20
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 20
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 18
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 18
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 claims 16
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims 12
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 12
- 229920002675 Polyoxyl Polymers 0.000 claims 11
- 125000005456 glyceride group Chemical group 0.000 claims 11
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims 9
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims 8
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 150000001336 alkenes Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- -1 fatty acid esters Chemical class 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161469940P | 2011-03-31 | 2011-03-31 | |
| US61/469,940 | 2011-03-31 | ||
| PCT/US2012/031453 WO2012135619A2 (en) | 2011-03-31 | 2012-03-30 | Intranasal benzodiazepine pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014509655A JP2014509655A (ja) | 2014-04-21 |
| JP2014509655A5 true JP2014509655A5 (https=) | 2015-05-14 |
Family
ID=46928023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502835A Pending JP2014509655A (ja) | 2011-03-31 | 2012-03-30 | 鼻腔内ベンゾジアゼピン薬剤学的組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20120252793A1 (https=) |
| EP (1) | EP2691100A4 (https=) |
| JP (1) | JP2014509655A (https=) |
| KR (1) | KR20140029426A (https=) |
| CN (1) | CN103619338B (https=) |
| AR (1) | AR085927A1 (https=) |
| AU (1) | AU2012236334B2 (https=) |
| BR (1) | BR112013024968A2 (https=) |
| CA (1) | CA2831308A1 (https=) |
| MX (1) | MX357800B (https=) |
| PH (2) | PH12013501915A1 (https=) |
| RU (2) | RU2013148120A (https=) |
| SG (2) | SG193958A1 (https=) |
| TW (1) | TWI601532B (https=) |
| WO (1) | WO2012135619A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101517415B1 (ko) | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| JP5929800B2 (ja) * | 2012-04-03 | 2016-06-08 | コニカミノルタ株式会社 | 定着液および画像形成方法 |
| US11020403B2 (en) * | 2017-06-02 | 2021-06-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| US11278492B2 (en) | 2018-01-05 | 2022-03-22 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
| WO2019182745A1 (en) * | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| JP7492918B2 (ja) | 2018-06-04 | 2024-05-30 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物 |
| CN111529489A (zh) * | 2020-04-17 | 2020-08-14 | 山东省药学科学院 | 一种含有地西泮的鼻腔喷雾剂 |
| EP4458414A3 (en) | 2020-12-04 | 2025-01-01 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having antifungal properties |
| CN118765194A (zh) | 2021-12-28 | 2024-10-11 | 阿尔库缇斯生物疗法股份有限公司 | 局部罗氟司特气溶胶泡沫 |
| EP4586999A1 (en) | 2022-09-15 | 2025-07-23 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998017315A2 (en) * | 1996-10-24 | 1998-04-30 | Alza Corporation | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
| MXPA02001612A (es) * | 1999-07-26 | 2003-10-14 | Sk Corp | Composiciones anti-convulsivas transnasales y procedimiento modular. |
| EP1539285B2 (en) * | 2002-09-03 | 2011-10-12 | Pharmacure Health Care AB | Nasal sprays |
| TW200824693A (en) * | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| US7745430B2 (en) * | 2006-11-15 | 2010-06-29 | Sk Holdings Co., Ltd. | Transnasal anticonvulsive pharmaceutical composition |
| NZ583265A (en) * | 2007-08-31 | 2012-01-12 | Archimedes Dev Ltd | Pharmaceutical compositions comprising a benzodiazepine drug and a non-aqueous vehicle comprising propylene glycol and propylene carbonate |
| KR101517415B1 (ko) * | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| WO2011034920A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
-
2012
- 2012-03-30 PH PH1/2013/501915A patent/PH12013501915A1/en unknown
- 2012-03-30 SG SG2013072319A patent/SG193958A1/en unknown
- 2012-03-30 WO PCT/US2012/031453 patent/WO2012135619A2/en not_active Ceased
- 2012-03-30 BR BR112013024968A patent/BR112013024968A2/pt not_active Application Discontinuation
- 2012-03-30 AU AU2012236334A patent/AU2012236334B2/en not_active Ceased
- 2012-03-30 CN CN201280017015.8A patent/CN103619338B/zh active Active
- 2012-03-30 MX MX2013011336A patent/MX357800B/es active IP Right Grant
- 2012-03-30 KR KR1020137028968A patent/KR20140029426A/ko not_active Ceased
- 2012-03-30 US US13/435,837 patent/US20120252793A1/en not_active Abandoned
- 2012-03-30 TW TW101111309A patent/TWI601532B/zh not_active IP Right Cessation
- 2012-03-30 RU RU2013148120/15A patent/RU2013148120A/ru not_active Application Discontinuation
- 2012-03-30 RU RU2018135967A patent/RU2018135967A/ru not_active Application Discontinuation
- 2012-03-30 CA CA2831308A patent/CA2831308A1/en not_active Abandoned
- 2012-03-30 SG SG10201602176RA patent/SG10201602176RA/en unknown
- 2012-03-30 EP EP12763553.0A patent/EP2691100A4/en not_active Ceased
- 2012-03-30 JP JP2014502835A patent/JP2014509655A/ja active Pending
- 2012-04-03 AR ARP120101144A patent/AR085927A1/es unknown
-
2014
- 2014-01-14 US US14/154,575 patent/US20140128381A1/en not_active Abandoned
-
2016
- 2016-06-30 US US15/198,884 patent/US20170151258A1/en not_active Abandoned
-
2017
- 2017-09-15 PH PH12017501688A patent/PH12017501688A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509655A5 (https=) | ||
| WO2009139589A3 (en) | Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant | |
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| MX358344B (es) | Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan. | |
| EP2827868A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH FATTY ACID ESTERS | |
| EP2598148A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH PEMETREXED WITH EXTENDED STORAGE STABILITY | |
| FR3007969B1 (fr) | Distributeur d'une dose unitaire d'une substance active sous une forme galenique solide | |
| EP2575787A4 (en) | PHARMACEUTICAL FORMULATIONS FROM STATINES AND OMEGA-3 FATTY ACIDS FOR THEIR ENCAPSULATION | |
| HRP20160203T1 (hr) | Pripravci koji sadrže 15-hepe i postupci njihove upotrebe | |
| DOP2012000264A (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| EA201290982A1 (ru) | Фармацевтические композиции, препятствующие злоупотреблению | |
| EP2822923A4 (en) | PREPARATION OF ALPHA, BETA-UNSATURATED CARBOXYLIC ACIDS AND ESTERS THEREOF | |
| DK4338805T3 (da) | Eicosapentaensyreethylester til brug for at reducere risikoen for ikke-dødeligt myokardieinfarkt hos en patient i statinbehandling | |
| EP2678075A4 (en) | SOLID FORMS OF A PHARMACEUTICALLY ACTIVE SUBSTANCE | |
| JP2014218522A5 (https=) | ||
| EP2800563A4 (en) | DPA-ENRICHED COMPOSITIONS OF MULTIPLE-UNSATURATED OMEGA-3 FATTY ACIDS IN A FREE ACID FORM | |
| JP2011140525A5 (https=) | ||
| PE20161373A1 (es) | Composiciones de liberacion retardada de linaclotida | |
| EP2643002A4 (en) | PHARMACEUTICAL FORMULATIONS WITH CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION | |
| EP2623100A4 (en) | Preparation for improving solubility of poorly soluble drug | |
| EA201100863A1 (ru) | Фармацевтическая композиция, включающая диклофенак и сложный эфир гидроксижирной кислоты и полиоксиалкилена | |
| FR2981572B1 (fr) | Compositions pharmaceutiques d'acide ursodesoxycholique | |
| EP2827867A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH GLYCERINESTERS | |
| EP2906244A4 (en) | SILK RESERVOIRS FOR THE DELAYED RELEASE OF ANTI-CANCER | |
| WO2014027777A3 (ko) | 신규한 우르솔릭산 유도체 및 이의 제조 방법 |